胆固醇系统完整性与GBA1和LRRK2突变载体认知衰退的关联
Julia Schumacher1,2, Nicola Ray3, Stefan Teipel4,5
1Department of Neurology, University Medical Center Rostock, 18147, Rostock, Germany. julia.schumacher@dzne.de.
NPJ Parkinson's disease
|July 1, 2024
概括
与GBA1突变携带者相比,患有LRRK2突变的帕金森病 (PD) 患者表现出持续的基础前脑体积增加和较慢的认知衰退. 这表明,在PD表型中,胆能系统的参与有所差异.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 帕金森病 (PD) 呈现出多种不同的临床表型,可能与GBA1和LRRK2突变的独特胆固醇系统参与有关.
- 胆固醇系统在认知功能中起着至关重要的作用,在PD中经常受到损害.
研究的目的:
- 为了研究和比较GBA1和LRRK2突变的无症状和症状携带者与异常性PD和对照者的胆固醇完整性.
- 探索基底前脑体积,白质完整性和不同PD遗传亚型的认知衰退之间的关系.
主要方法:
- 使用免费水校正模型的扩散张力成像 (DTI) 来评估基础前脑体积和白质路径 (NBM-皮质,PNN-体质) 在一个大队列 (PPMI) 中.
- 采用贝叶斯式ANCOVA和线性混合模型来分析5年来群体差异和认知轨迹的关联.
主要成果:
- 与对照组相比,在无症状的GBA1和LRRK2载体中观察到基底前脑体积增加.
- 症状的LRRK2-PD显示出比GBA1-PD和异常性PD更大的基础前脑体积.
- 异形性PD和GBA1-PD患者在各个领域表现出认知能力下降,而LRRK2-PD患者的处理速度主要下降.
结论:
- 两种LRRK2和GBA1突变都与无症状阶段的基础前脑体积扩张有关.
- 这种扩张在LRRK2-PD中持续存在,与较慢的认知衰退相关,表明具有保护作用或不同的疾病机制.
- 这些发现突出了基于遗传突变的PD病变发生过程中的不同胆固醇系统参与.
更多相关视频
09:15Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain
Published on: February 5, 2020
5.5K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K